Anthera Pharmaceuticals Receives a Hold from Roth Capital
In a report issued on June 29, Jotin Marango from Roth Capital maintained a Hold rating on Anthera Pharmaceuticals (NASDAQ: ANTH). The company’s shares closed on Friday at $0.08, close to its 52-week low of $0.07.
According to TipRanks.com, Marango is a 4-star analyst with an average return of 24.5% and a 50.0% success rate. Marango covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Aptevo Therapeutics Inc, and Aptose Biosciences.
Anthera Pharmaceuticals has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on Anthera Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.72 million. In comparison, last year the company had a net profit of $313K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy.